×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
IMVT – immunovant, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
IMVT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/20
09:12 am
imvt
Immunovant: Best-In-Class Ambitions, Still Unproven [Seeking Alpha]
Low
Report
Immunovant: Best-In-Class Ambitions, Still Unproven [Seeking Alpha]
4/15
01:18 pm
imvt
Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight [Yahoo! Finance]
Low
Report
Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight [Yahoo! Finance]
4/15
08:51 am
imvt
Immunovant (IMVT) had its "neutral" rating reaffirmed by The Goldman Sachs Group, Inc..
Low
Report
Immunovant (IMVT) had its "neutral" rating reaffirmed by The Goldman Sachs Group, Inc..
4/10
06:16 am
imvt
Immunovant (IMVT) had its "sell (d-)" rating reaffirmed by Weiss Ratings.
Medium
Report
Immunovant (IMVT) had its "sell (d-)" rating reaffirmed by Weiss Ratings.
4/2
08:09 pm
imvt
Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM [Yahoo! Finance]
Low
Report
Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM [Yahoo! Finance]
4/2
01:35 pm
imvt
Immunovant Batoclimab Flops in Phase 3 TED as Roivant Expands Brepocitinib Into LPP [Yahoo! Finance]
Low
Report
Immunovant Batoclimab Flops in Phase 3 TED as Roivant Expands Brepocitinib Into LPP [Yahoo! Finance]
4/2
07:08 am
imvt
Immunovant shares plunge after phase 3 trials fails to meet primary endpoint [Yahoo! Finance]
Medium
Report
Immunovant shares plunge after phase 3 trials fails to meet primary endpoint [Yahoo! Finance]
4/2
05:40 am
imvt
Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) [Yahoo! Finance]
High
Report
Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) [Yahoo! Finance]
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/10
04:05 pm
imvt
Form 4 Immunovant, Inc. For: Apr 08 Filed by: Van Tuyl Christopher
Low
Report
Form 4 Immunovant, Inc. For: Apr 08 Filed by: Van Tuyl Christopher
4/10
04:04 pm
imvt
Form 4 Immunovant, Inc. For: Apr 08 Filed by: Gloria Melanie
Low
Report
Form 4 Immunovant, Inc. For: Apr 08 Filed by: Gloria Melanie
4/10
04:02 pm
imvt
Form 4 Immunovant, Inc. For: Apr 08 Filed by: Stout Jay S
Low
Report
Form 4 Immunovant, Inc. For: Apr 08 Filed by: Stout Jay S
4/9
04:31 pm
imvt
Form 4 Immunovant, Inc. For: Apr 07 Filed by: Torti Frank
Medium
Report
Form 4 Immunovant, Inc. For: Apr 07 Filed by: Torti Frank
4/9
04:29 pm
imvt
Form 4 Immunovant, Inc. For: Apr 07 Filed by: Fromkin Andrew J.
Medium
Report
Form 4 Immunovant, Inc. For: Apr 07 Filed by: Fromkin Andrew J.
4/9
04:27 pm
imvt
Form 4 Immunovant, Inc. For: Apr 07 Filed by: Hughes Douglas J.
Medium
Report
Form 4 Immunovant, Inc. For: Apr 07 Filed by: Hughes Douglas J.
4/9
04:25 pm
imvt
Form 4 Immunovant, Inc. For: Apr 07 Filed by: Pande Atul
Medium
Report
Form 4 Immunovant, Inc. For: Apr 07 Filed by: Pande Atul
4/9
04:24 pm
imvt
Form 4 Immunovant, Inc. For: Apr 07 Filed by: Bauer Jake
Medium
Report
Form 4 Immunovant, Inc. For: Apr 07 Filed by: Bauer Jake
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/30
Immunovant Announces Positive Clinical Results from Ongoing Phase 2a Proof-of-Concept Study of IMVT-1401, A Novel Investigational Anti-FcRn Antibody Delivered by Subcutaneous Injection, in Thyroid Eye Disease
23.1%
4/14 Immunovant Announces Pricing of $121.2 Million Public Offering 12.8%
12/19 Immunovant Sciences Ltd. Closes Transaction with Health Sciences Acquisitions Corporation 12.1%
1/9 Immunovant (NASDAQ: IMVT) is now covered by analysts at Chardan Capital. They set a "buy" rating on the stock. 6.9%
2/14 Immunovant Reports Financial Results for the Quarter and Nine Months Ending December 31, 2019 6.4%
2/14 Form SC 13G/A Immunovant, Inc. Filed by: Cormorant Asset Management, LP 5.7%
4/8 Form S-1/A Immunovant, Inc. 4.3%
1/10 Immunovant (NASDAQ: IMVT) is now covered by analysts at SunTrust Banks, Inc.. They set a "buy" rating on the stock. 3.8%
3/4 Immunovant (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at Nomura. They now have a $27.00 price target on the stock. 3.3%
12/20 Form 4 Health Sciences Acquisit For: Dec 18 Filed by: Health Sciences Holdings, LLC 3.2%
4/14 Immunovant Announces Pricing of $121.2 Million Public Offering 12.8%
12/19 Immunovant Sciences Ltd. Closes Transaction with Health Sciences Acquisitions Corporation 12.1%
1/9 Immunovant (NASDAQ: IMVT) is now covered by analysts at Chardan Capital. They set a "buy" rating on the stock. 6.9%
2/14 Immunovant Reports Financial Results for the Quarter and Nine Months Ending December 31, 2019 6.4%
2/14 Form SC 13G/A Immunovant, Inc. Filed by: Cormorant Asset Management, LP 5.7%
4/8 Form S-1/A Immunovant, Inc. 4.3%
1/10 Immunovant (NASDAQ: IMVT) is now covered by analysts at SunTrust Banks, Inc.. They set a "buy" rating on the stock. 3.8%
3/4 Immunovant (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at Nomura. They now have a $27.00 price target on the stock. 3.3%
12/20 Form 4 Health Sciences Acquisit For: Dec 18 Filed by: Health Sciences Holdings, LLC 3.2%
TOP News Decliners
2/12
Form SC 13G/A Immunovant, Inc. Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-7.3%
2/24 Immunovant (NASDAQ: IMVT) is now covered by analysts at Svb Leerink Llc. They set an "outperform" rating and a $24.00 price target on the stock. -6.0%
3/30 Form 8-K Immunovant, Inc. For: Mar 30 -6.0%
1/17 Form S-1 Immunovant, Inc. -5.5%
2/19 Form 3 Immunovant, Inc. For: Feb 18 Filed by: Venker Eric -3.8%
2/21 Immunovant (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at Chardan Capital. -2.8%
2/5 Immunovant (NASDAQ: IMVT) is now covered by analysts at Nomura. They set a "buy" rating and a $27.00 price target on the stock. -2.8%
4/16 Immunovant Announces Closing of $139.4 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares -2.1%
2/10 Immunovant to Present at the 9th Annual SVB Leerink Global Healthcare Conference -2.0%
1/7 Immunovant (NASDAQ: IMVT) is now covered by analysts at Robert W. Baird. They set an "outperform" rating on the stock. -1.9%
2/24 Immunovant (NASDAQ: IMVT) is now covered by analysts at Svb Leerink Llc. They set an "outperform" rating and a $24.00 price target on the stock. -6.0%
3/30 Form 8-K Immunovant, Inc. For: Mar 30 -6.0%
1/17 Form S-1 Immunovant, Inc. -5.5%
2/19 Form 3 Immunovant, Inc. For: Feb 18 Filed by: Venker Eric -3.8%
2/21 Immunovant (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at Chardan Capital. -2.8%
2/5 Immunovant (NASDAQ: IMVT) is now covered by analysts at Nomura. They set a "buy" rating and a $27.00 price target on the stock. -2.8%
4/16 Immunovant Announces Closing of $139.4 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares -2.1%
2/10 Immunovant to Present at the 9th Annual SVB Leerink Global Healthcare Conference -2.0%
1/7 Immunovant (NASDAQ: IMVT) is now covered by analysts at Robert W. Baird. They set an "outperform" rating on the stock. -1.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: